Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$9.56 ▼ -5.25
(-35.45%)
MKT CAP: $4.33B • VOL: 59.23M
52W L $2 52W H $15
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$8
MEDIAN
$11
MEAN
$11
HIGH
$13
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE IOVA TAPE
IOVA // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $11.57 | $10.99 | 2025-02-14 | $8.70 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $12.05 | $11.28 | 2025-02-06 | $8.99 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $10.90 | $10.52 | 2025-01-29 | $9.18 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $9.75 | — | 2025-01-17 | $9.37 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $8.41 | $9.08 | 2025-01-09 | $8.51 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $11.38 | $9.94 | 2024-12-18 | $8.32 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $9.27 | $9.66 | 2024-12-04 | $8.89 | -4.3% | 48% | C |